Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb/IV, Multicenter, Randomized, Open-Label, Two-Arm Study to Investigate the Efficacy, Safety, and Durability of Faricimab Administered up to Every 24 Weeks in Patients With Neovascular Age-Related Macular Degeneration

NCT06795048 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT06795048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06795048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb/IV, Multicenter, Randomized, Open-Label, Two-Arm Study to Investigate the Efficacy, Safety, and Durability of Faricimab Administered up to Every 24 Weeks in Patients With Neovascular Age-Related Macular Degeneration
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Active, not recruiting
Start date
March 14, 2025
Completion date
September 20, 2027
Enrollment
274 (estimated)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration (namd)